Company Encyclopedia
View More
name
WONDFO BIOTECH
300482.SZ
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution.
886.85 B
300482.SZMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking36/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.73%C
    • Profit Margin10.08%B
    • Gross Margin52.15%B
  • Growth ScoreD
    • Revenue YoY-12.52%E
    • Net Profit YoY-50.47%D
    • Total Assets YoY-1.45%D
    • Net Assets YoY-0.11%C
  • Cash ScoreC
    • Cash Flow Margin992.02%B
    • OCF YoY-12.52%E
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio16.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WONDFO BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 134 million yuan, a decrease of 69.32%

    According to the Zhitong Finance APP, WONDFO BIOTECH released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders of the listed company was 134 million yuan, a year-on-year decrease of 69.32%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 82.6416 million yuan, a year-on-year decrease of 78.67%. The basic earnings per share were 0.28 yuan

    Zhitong·
    SZ
    300482
    -0.95%
    Zhitong·
    SZ
    300482
    -0.95%

    WONDFO BIOTECH plans to spend between 30 million and 60 million yuan to implement a share repurchase

    According to the Zhitong Finance APP, WONDFO BIOTECH announced that the company plans to use its own funds to repurchase some of its shares through centralized bidding. The repurchased shares will be used entirely for implementing equity incentives or employee stock ownership plans. The total amount of funds for the repurchase will not be less than 30 million yuan (inclusive) and not exceed 60 million yuan (inclusive), with the repurchase price not exceeding 34.66 yuan per share (inclusive). The repurchase period is within 6 months from the date the board of directors approves the final repurchase plan

    Zhitong·
    SZ
    300482
    -0.95%
    Zhitong·
    SZ
    300482
    -0.95%

    WONDFO BIOTECH received multiple medical device registration certificates

    According to the Zhitong Finance APP, WONDFO BIOTECH announced that the company recently received the medical device registration certificate issued by the Guangdong Provincial Drug Administration. The product names are: Fibrin (ogen) Degradation Product Determination Kit (Immunoturbidimetric Method), Fibrinogen Determination Kit (Coagulation Method), D-Dimer Determination Kit (Immunoturbidimetric Method), Anti Xa Determination Kit (Chromogenic Substrate Method)

    Zhitong·
    SZ
    300482
    -0.95%
    Zhitong·
    SZ
    300482
    -0.95%

    WONDFO BIOTECH signs strategic agreement with the Ministry of Health of Côte d'Ivoire

    According to WONDFO BIOTECH, recently, WONDFO BIOTECH signed a strategic agreement with the Ministry of Health of Côte d'Ivoire. According to the agreement, WONDFO BIOTECH will carry out in-depth cooperation with the healthcare system of Côte d'Ivoire in various fields such as production, education, research, and application

    Zhitong·
    SZ
    300482
    -0.95%
    Zhitong·
    SZ
    300482
    -0.95%

    WONDFO BIOTECH: Fully automatic nucleic acid amplification analyzer has obtained the medical device registration certificate

    On the evening of August 20th, WONDFO BIOTECH announced that the company recently received the medical device registration certificate for the fully automated nucleic acid amplification analyzer issued by the National Medical Products Administration. This product is based on the principles of magnetic bead nucleic acid extraction and polymerase chain reaction technology, and is used in conjunction with matching detection reagents for qualitative detection of target nucleic acids derived from human samples in clinical settings, including pathogens and human gene projects

    Zhitong·
    SZ
    300482
    -0.95%
    Zhitong·
    SZ
    300482
    -0.95%
    © 2025 Longbridge｜Disclaimer